Sudeep Pharma Final Dividend FY26 — ₹1.50/Share, Record Date 23 Jul 2026

At its board meeting on Thursday, 21 May 2026, the Board of Directors of Sudeep Pharma Limited recommended a final dividend of ₹1.50 per equity share (150% of the ₹1 face value) for the year ended 31 March 2026. The recommendation is subject to shareholder approval at the forthcoming 37th Annual General Meeting.

This is a meaningful milestone: Sudeep Pharma only listed on the NSE and BSE on 28 November 2025 at an IPO price of ₹593. FY2025-26 is therefore its first dividend declaration as a publicly listed company. The board also approved the FY26 audited results, the appointment of a cost auditor and secretarial auditor, alongside the dividend proposal.

The dividend will be paid out of standalone distributable profits. Company-level (standalone) net profit for FY26 was ₹107.58 Cr, comfortably covering the ₹16.94 Cr outflow. Ratification at the AGM on 4 August 2026 is procedural but legally required before payment can be released.

Yield reality check. A sub-0.2% yield is negligible for an income-seeking investor. It is not the result of a falling share price or a distressed business — quite the opposite. The stock has re-rated sharply since listing (trading well above its ₹593 IPO price), and the company is deliberately retaining almost all of its earnings to fund a large capex and diversification programme. In short, the low yield reflects a growth-and-retention strategy, not weakness. Anyone buying Sudeep Pharma for dividends is buying the wrong stock; the thesis here is capital appreciation, not income.

Payer classification: Early-Stage / Maiden Payer. As a company that listed only in November 2025, Sudeep Pharma has no track record of listed-company dividends. There is therefore no basis yet to judge consistency, growth trend, or cut/suspension history. Whether this becomes a "consistent payer" depends entirely on how the next two-to-three years unfold, especially as the battery-materials capex programme competes for cash. Treat the ₹1.50 as a signal of intent, not a policy.

Operating leverage. Consolidated EBITDA margin was a healthy ~34.5%. However, on a full-year basis the Speciality Ingredients segment grew ~63% (₹171.5 Cr → ₹279.6 Cr) while the core Pharmaceutical, Food & Nutrition segment was roughly flat, confirming that the mix shift and the acquired business are doing the heavy lifting. Note also that reported EPS has been restated for the conversion of 1.41 crore preference shares (CCPS) into equity, so year-on-year EPS is like-for-like.

How is the dividend funded? Not by consolidated free cash flow (which is negative). It is funded by a combination of standalone operating cash flow and the company's substantial cash and deposit reserves, which include ₹75.81 Cr of still-unutilised IPO proceeds parked in bank deposits. Because the dividend is tiny relative to these reserves, affordability is not in question — but investors should recognise the payout is being made while the group is cash-flow negative at the consolidated level due to heavy investment.

The balance sheet is strong and lightly geared — net debt is a trivial 0.15x EBITDA, and the group carries ₹114.65 Cr of cash and deposits. Two items warrant a flag: (1) ₹68.24 Cr of goodwill sits on the books from the Ireland (NSS) acquisition, and the purchase-price allocation is still provisional — final numbers were due before 30 June 2026 and could shift; (2) roughly ₹75.81 Cr of IPO cash remains undeployed, earmarked for machinery at the Nandesari facility. Debt is not rising to fund the dividend.

Verdict. At ₹1.50 the dividend is trivially affordable and clearly sustainable in the narrow sense — earnings, cash and the balance sheet all cover it many times over. The nuance is that sustainability of the amount and sustainability of growth in the amount are different questions. With consolidated FCF currently negative and a ₹300 Cr battery-materials capex commitment ahead, do not assume the dividend will scale quickly. A stable-to-modestly-rising token payout is the realistic base case.

Sudeep Pharma occupies a niche — mineral-based pharmaceutical excipients and food/nutrition specialty ingredients — with few clean, directly comparable Indian listed peers. Rather than populate this table with mismatched names, we have deliberately left peer cells as "Not Independently Verified". What can be said with confidence: its ~34.5% EBITDA margin and ~19.6% ROE are strong for a specialty ingredients maker, while its sub-0.2% yield places it firmly among low-yield, growth-oriented names rather than income stocks. Editors should slot in verified peer figures (e.g. from screener.in) before publication.

With promoters (the Bhayani family and group entities) holding 76.15%, roughly ₹12.90 Cr of the ₹16.94 Cr dividend flows to the promoter group, leaving about ₹4.04 Cr for non-promoter shareholders (FIIs, DIIs and the public). Because the payout is so small relative to profits, this is not a case of a controlling family extracting cash — retention dominates. The distribution is proportionate to ownership and consistent across all shareholders; there is no differential class benefit.

Since April 2020, dividends in India are taxable in the hands of the shareholder at their applicable income-tax slab rate — there is no longer any Dividend Distribution Tax at the company level. The company deducts TDS at 10% for resident shareholders only if total dividend from that company exceeds ₹5,000 in the financial year (20% if PAN is not furnished). TDS deducted can be adjusted against your final tax liability.

Worked Example — Investor holding 1,000 shares

Illustrative for a 30%-slab investor. Even though no TDS is withheld here (dividend under ₹5,000), the ₹1,500 is still added to taxable income and taxed at the investor's slab. Consult a tax advisor for your situation.

Sudeep Pharma's maiden ₹1.50 dividend is best read as a gesture of shareholder friendliness from a newly-listed, growth-focused company — not as an income opportunity. On the positive side: profits grew strongly (+25.6% consolidated PAT), margins are high (~34.5% EBITDA), the balance sheet is nearly debt-free (net debt/EBITDA 0.15x), and the payout is covered many times over by earnings and cash.

On the cautious side: the yield is a negligible ~0.18%, consolidated free cash flow was negative, cash conversion was a weak 40%, the impressive top-line growth was substantially acquisition-driven (with standalone core revenue actually falling), and the company is embarking on a large, unproven capital programme in battery materials. Combined with a rich valuation, the investment case rests on execution of growth ambitions, not on the dividend. We present the evidence; the decision is yours.